Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study
Khurum Khan,Mihaela Rata,David Cunningham,Dow-Mu Koh,Nina Tunariu,Jens C Hahne,George Vlachogiannis,Somaieh Hedayat,Silvia Marchetti,Andrea Lampis,Mahnaz Darvish Damavandi,Hazel Lote,Isma Rana,Anja Williams,Suzanne A Eccles,Elisa Fontana,David Collins,Zakaria Eltahir,Sheela Rao,David Watkins,Naureen Starling,Jan Thomas,Eleftheria Kalaitzaki,Nicos Fotiadis,Ruwaida Begum,Maria Bali,Massimo Rugge,Eleanor Temple,Matteo Fassan,Ian Chau,Chiara Braconi,Nicola Valeri
DOI: https://doi.org/10.1136/gutjnl-2017-314178
IF: 24.5
2017-08-08
Gut
Abstract:Objective Regorafenib demonstrated efficacy in patients with metastatic colorectal cancer (mCRC). Lack of predictive biomarkers, potential toxicities and cost-effectiveness concerns highlight the unmet need for better patient selection. Design Patients with RAS mutant mCRC with biopsiable metastases were enrolled in this phase II trial. Dynamic contrast-enhanced (DCE) MRI was acquired pretreatment and at day 15 post-treatment. Median values of volume transfer constant (K trans ), enhancing fraction (EF) and their product KEF (summarised median values of K trans × EF) were generated. Circulating tumour (ct) DNA was collected monthly until progressive disease and tested for clonal RAS mutations by digital-droplet PCR. Tumour vasculature (CD-31) was scored by immunohistochemistry on 70 sequential tissue biopsies. Results Twenty-seven patients with paired DCE-MRI scans were analysed. Median KEF decrease was 58.2%. Of the 23 patients with outcome data, >70% drop in KEF (6/23) was associated with higher disease control rate (p=0.048) measured by RECIST V. 1.1 at 2 months, improved progression-free survival (PFS) (HR 0.16 (95% CI 0.04 to 0.72), p=0.02), 4-month PFS (66.7% vs 23.5%) and overall survival (OS) (HR 0.08 (95% CI 0.01 to 0.63), p=0.02). KEF drop correlated with CD-31 reduction in sequential tissue biopsies (p=0.04). RAS mutant clones decay in ctDNA after 8 weeks of treatment was associated with better PFS (HR 0.21 (95% CI 0.06 to 0.71), p=0.01) and OS (HR 0.28 (95% CI 0.07–1.04), p=0.06). Conclusions Combining DCE-MRI and ctDNA predicts duration of anti-angiogenic response to regorafenib and may improve patient management with potential health/economic implications.
gastroenterology & hepatology